# Pizarra — PT-pseudo_2eef4115a253 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2eef4115a253
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 59-year-old male
  - PSA: 2.11 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.058 ng/mL²
  - PSA velocity: -0.04 ng/mL/yr
  - Prior PSA: 2.1 ng/mL
  - Prostate volume: 36.08 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7737494 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 2.11 ng/mL. PI-RADS 4. PSAD 0.06. Prostate volume 36 mL. csPCa 0.77.

Vitals: weight 85 kg, height 182 cm, BMI 25.7, BP 117/84 mmHg, HR 73 bpm. Smoking: Ex-smoker (36 pack-yr, quit 2021).

Chief complaint: Evaluation requested after imaging revealed a left peripheral zone abnormality alongside a recent PSA elevation.

History: At 59 years of age, the patient works as a retired shopkeeper. He is divorced and currently resides with his partner. A former smoker, he accumulated 36 pack-years before cessation in 2021. Daily activity remains largely sedentary, punctuated by brief walks. Moderate voiding complaints dominate the history, specifically nocturia and a diminished urinary stream, correlating with an IPSS score of 19. He explicitly denies haematuria or pelvic discomfort. No chronic comorbidities exist, and he takes no active medications. Alcohol intake averages two units per week. An Arabic interpreter will be required during the consultation to facilitate precise dialogue.

Physical examination: DRE — texture: symmetrically smooth; consistency: normal; asymmetry: absent; nodules: none. Vital parameters remain stable, recording a blood pressure of 117/84 mmHg alongside a regular heart rate of 73 bpm. Thoracic auscultation reveals clear lung fields, and no peripheral oedema is observed.

Patient info: retired shopkeeper; Divorced; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 2 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Pulmonary function test — known COPD follow-up; Vascular surgery — varicose veins consult.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.77 +/- 0.16   (95% CI 0.39-0.98)

Where the uncertainty comes from:
  - aleatoric  dA = 0.13  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 7.3 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=0.0, psa=2.11, age=59.0, psad=0.058, dre_ord=0.0, vol=36.08, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (-0.04 ng/mL/yr), the specific findings from the mpMRI report (beyond the PI-RADS 4 score), or the full laboratory panel results.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy with a high probability (0.77), but the uncertainty is high (error bar $\pm 0.16$). The prior might be wrong because the PI-RADS 4 score is relatively low risk, yet the csPCa predicted probability is high (0.7737494). Furthermore, the prior does not account for the fact that the prior biopsy status is 'None', meaning the decision is purely based on imaging and labs, which might be insufficient given the high predicted probability.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details the extent/characteristics of the left peripheral zone abnormality, it would refine the PI-RADS 4 assessment.
  <document> PSA history (trend) -> If the trend shows a significant rise, it would increase the urgency for further investigation.
  <document> laboratory results (full panel) -> If the lab panel shows any markers (e.g., PSA density context, other inflammatory markers), it could modify the risk assessment.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the LUTS or any prior discussions about the PSA trajectory.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number.
  
  **radiology / mpMRI report**
  Radboudumc | 28 Jan 2025 | Prostate Multiparametric MRI
  Clinical Context: Risk stratification alongside PSA 2.11 ng/mL evaluation.
  FINDINGS: The gland measures 36.08 mL overall. A roughly 12 mm focal hypointense area occupies the left peripheral zone at mid-gland level. T2-weighted sequences highlight this region. Diffusion-weighted imaging shows marked restriction, confirmed by low apparent diffusion coefficient signals. Dynamic contrast studies demonstrate early, focal enhancement compared to adjacent tissue. Pelvic lymph nodes appear unremarkable. No seminal vesicle invasion or extracapsular extension is visible.
  IMPRESSION: PI-RADS 4 lesion in the left peripheral zone mid-gland. Prostate volume 36.08 mL yielding a PSA density of 0.058 ng/mL/mL. csPCa predicted probability 0.7737494.

  **PSA history**
  [{"date": "Jan 2023", "val": 0.5}, {"date": "Sep 2023", "val": 1.7}, {"date": "May 2024", "val": 1.9}, {"date": "Feb 2025", "val": 2.11}]

  **laboratory results**
  [{"name": "PSA", "val": "2.1 ng/mL", "date": "26 Dec 2024", "flag": ""}, {"name": "Free PSA", "val": "0.36 ng/mL", "date": "26 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "17%", "date": "26 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "14.7 g/dL", "date": "26 Dec 2024", "flag": ""}, {"name": "WBC", "val": "4.2 x10^9/L", "date": "26 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "274 x10^9/L", "date": "26 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "97 umol/L", "date": "26 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "26 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "13.2 nmol/L", "date": "26 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "87 U/L", "date": "26 Dec 2024", "flag": ""}, {"name": "LDH", "val": "167 U/L", "date": "26 Dec 2024", "flag": ""}]

  **previous GP / urology consultation notes**
  [{"date": "04 Oct 2024", "author": "Dr. E. Mulder (GP)", "text": "Discussion centered on recent laboratory data. PSA levels increased to 2.1 ng/mL, a step up from the 1.6 ng/mL recorded in September 2023. Moderate lower urinary tract complaints were noted, yielding an IPSS score of 19. Given the upward trajectory, a multiparametric MRI was scheduled for detailed assessment."}, {"date": "12 Feb 2023", "author": "Dr. E. Mulder (GP)", "text": "Routine health screening included a PSA test. The measured value stood at 1.6 ng/mL, aligning with age-appropriate norms. Voiding function remained entirely asymptomatic. Annual laboratory follow-up was arranged."}]

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 4 lesion in the left peripheral zone mid-gland.
  PSA velocity of -0.04 ng/mL/yr (though the trend shows a rise from 1.9 to 2.11 ng/mL).
  csPCa predicted probability of 0.7737494.
  PSA trend shows a recent increase (1.9 ng/mL to 2.11 ng/mL).
  
  AGAINST sampling this patient now:
  DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
  PSA value of 2.11 ng/mL (which is relatively low).

WHERE THIS LEANS
  The retrieved evidence strongly supports further investigation due to the PI-RADS 4 finding and the high csPCa predicted probability, which aligns with the statistical prior. The recent PSA rise also adds weight to the need for biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence converges on further investigation due to a PI-RADS 4 lesion in the left peripheral zone and a high csPCa predicted probability of 0.7737494. This decision is driven by the PI-RADS 4 score and the recent PSA increase from 1.9 ng/mL to 2.11 ng/mL, which aligns with the statistical prior. The statistical prior favoured biopsy, and the retrieved evidence strongly supports this need for tissue sampling.

Variables that carried weight: age=noted, psa=important, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
